Vericel (VCEL) Q4 2025 earnings review
Record Volumes and Exploding Margins, But 2026 Requires Investment
Vericel capped off 2025 with an exceptionally strong Q4, driven by the successful adoption of MACI Arthro. Total revenue grew 23% YoY to $92.9M, and the volume leverage resulted in a massive 40% Adjusted EBITDA margin. While the core MACI engine is accelerating, management is setting a prudent tone for 2026. Guidance implies a deceleration in revenue growth to ~16% and an Adjusted EBITDA margin of 27% as the company absorbs the costs of a newly expanded sales force, a new manufacturing facility, and the initiation of the MACI Ankle clinical trial.
🐂 Bull Case
The transition to a less-invasive arthroscopic delivery method (MACI Arthro) is expanding the addressable market. Q4 saw the highest number of MACI implants, implanting surgeons, and biopsies in the product's history.
With the heavy lifting of the new Burlington manufacturing facility largely complete, Vericel generated $52M in operating cash flow in FY25, ending the year with $200M in cash and zero debt.
🐻 Bear Case
While Q4 Adjusted EBITDA margins hit an incredible 40%, FY26 guidance calls for ~27%. The P&L will have to absorb a full year of expanded sales force costs and clinical trial expenses for MACI Ankle.
Burn Care revenue dropped sequentially from $11.8M in Q3 to just $8.8M in Q4. The inherent unpredictability of Epicel orders due to patient health cancellations remains a persistent drag on forecasting clarity.
⚖️ Verdict: 🟢
Bullish. Vericel is executing flawlessly on its core product. The 2026 margin compression is driven by necessary, growth-funding investments (R&D and Sales) rather than pricing or competitive pressure, positioning the company for long-term dominance.
Key Themes
MACI Arthro Accelerating Surgeon Adoption
The rollout of MACI Arthro has fundamentally shifted the growth trajectory. The company has now trained approximately 1,000 surgeons. This less-invasive technique is not only driving higher utilization among existing users but expanding penetration into new anatomical segments like the trochlea and small femoral condyles. MACI revenue grew 23% YoY in Q4 to $84.1M.
Sales Force Expansion Completed
Vericel successfully expanded its MACI sales force from 76 to roughly 100 territories in the second half of 2025. This front-loaded investment was completed in time to capitalize on the historically strong Q4 and sets a robust foundation to hunt for new surgeons and deepen penetration in FY26.
Burn Care Growth Reversing Sequentially
Despite a strong Q3 ($11.8M), Q4 Burn Care revenue (Epicel and NexoBrid) fell sequentially to $8.8M. Management had previously lowered H2 expectations to a '$10M per quarter run rate' due to a higher ratio of canceled cases. Q4 coming in below that revised run rate highlights the persistent, structural volatility of the severe burn market.
2026 Earnings Power Temporarily Capped by Investments
Despite exiting Q4 with a record 79% Gross Margin and 40% Adjusted EBITDA Margin, 2026 guidance is anchored to ~75% Gross Margin and ~27% EBITDA Margin. The company must digest depreciation and start-up costs for the new Burlington facility, full-year costs of the expanded sales team, and the MACI Ankle MASCOT Phase III study. Margins are stable annually but reversing heavily from the Q4 exit rate.
Macro Resilience: Tariff Impacts Negligible
Management proactively confirmed that current and proposed tariffs will have a 'negligible' impact on COGS and gross margins. Vericel manufactures its therapies in the U.S., sources revenue domestically, and maintains significant safety stock for key materials, insulating it from global supply chain shocks.
Technology & Pipeline Progression: MACI Ankle
The company officially initiated the MACI Ankle MASCOT clinical study. Targeting lesions greater than 1.2 sq cm, this prospective Phase III trial is a critical step toward unlocking a potential $1 billion new addressable market by the end of the decade.
Other KPIs
Cash generation has reached an inflection point, with operating cash flow supporting a fortress balance sheet of $200M in cash and investments with zero debt. This is up significantly from $166M at the end of 2024.
Accelerating significantly from 69% in Q1 and 78% in the prior year's Q4. The margin expansion demonstrates incredible operating leverage as MACI volumes scale, though management is conservatively guiding ~75% for FY26 as new facility depreciation kicks in.
Up 27% YoY from $40.0M in 24Q4. The rapid increase is driven by headcount additions (sales force expansion), higher employee compensation tied to performance, and MACI tech transfer/start-up activities at the Burlington facility.
Guidance
Decelerating. The midpoint of $321M implies 16.2% YoY growth, a step down from the 23% YoY growth delivered in Q4 and the 16.5% delivered for full-year 2025. Management typically sets a prudent initial bar, especially given anticipated Q1 seasonality.
Decelerating. The midpoint of $283M implies 18.2% YoY growth, compared to 21% growth for FY25 and 23% in Q4. Growth relies on the newly expanded sales force converting the recent spike in Arthro biopsies into higher implant volumes.
Stable annually but Reversing sequentially. Up slightly from 26% for FY25, but a drastic drop from the 40% exit rate in Q4. This reflects a full year of burdened OPEX (Ankle trial, 100-territory sales force) against a lower seasonal revenue base in H1 2026.
Key Questions
Burn Care Stabilization
Burn Care revenue fell back to $8.8M in Q4 despite previous commentary suggesting a $10M quarterly run-rate. Have patient cancellation rates worsened structurally, or is this simply quarterly timing?
Q1 2026 Seasonality
You noted in previous calls that Q1 tends to see a slower growth rate. With the expanded sales force fully in place by January 1, should we expect a smoother transition into early 2026, or will the historical Q1 dip persist?
Burlington Facility Impact
As MACI commercial manufacturing transitions to the new facility in 2026, what specific headwind to gross margin is baked into the ~75% guidance, and how long until the new facility becomes margin-accretive?
MACI Arthro Conversion Cycle
With 1,000 surgeons now trained, are you seeing any changes in the historical 4-6 month lag from biopsy to implant, given the less invasive nature of the Arthro procedure?